Growth Hormone Secretagogues: Ipamorelin and CJC-1295

Growth hormone secretagogues (GHS) are compounds that stimulate pituitary GH release. Two classes dominate the peptide research literature: GH-releasing hormone (GHRH) analogues like CJC-1295, and GH-releasing peptides (GHRPs) like Ipamorelin. Understanding why these two types are often studied together requires understanding how GH release is physiologically regulated — and why the regulatory system exists in the first place.

Two Pathways, One Output

Pituitary GH secretion is governed by a dual regulatory system. GHRH (from the hypothalamus) drives GH synthesis and release via the GHRH receptor on somatotrophs. Ghrelin and the GHRPs act through a distinct receptor (GHS-R1a) on the same cells. Both pathways converge on adenylyl cyclase and intracellular Ca²⁺ signaling, but through separate G-protein cascades.

Activating both pathways simultaneously produces a supra-additive (synergistic) GH pulse. That's the mechanistic basis for co-administration protocols in research. It isn't just theoretical, either. Human studies have demonstrated GH pulse amplitudes with combined GHRH + GHRP administration that exceed what either produces alone by factors of 3–10.

Ipamorelin: The Selective GHRP

Ipamorelin was developed by Novo Nordisk in the late 1990s as a third-generation GHRP. Its key distinction from earlier GHRPs (GHRP-2, GHRP-6) is receptor selectivity: Ipamorelin stimulates GH release without meaningfully elevating cortisol, prolactin, or ACTH at research-relevant doses. The earlier GHRPs strongly activated those off-target pathways. GHRP-2 and GHRP-6 both produce significant cortisol and prolactin elevation, which limits their utility as research tools.

• Receptor: GHS-R1a agonist (same receptor as the endogenous hormone ghrelin)
• GH stimulation: Dose-dependent; comparable to GHRP-6 in peak GH amplitude
• Cortisol/ACTH: Minimal elevation versus other GHRPs at standard doses
• Prolactin: No significant effect at physiological doses
• Half-life: Approximately 2 hours; produces discrete GH pulses rather than sustained elevation
• Clinical testing: Studied in Phase I and II trials by Novo Nordisk for multiple indications before development was discontinued for commercial reasons

Ipamorelin is the first GHRP receptor agonist with a selectivity for GH release similar to that of GHRH, combined with efficacy comparable to GHRP-6 — making it a highly selective tool for studying the GHS-R1a pathway.

— Raun K et al., European Journal of Endocrinology, 1998

CJC-1295: The Stable GHRH Analogue

Native GHRH(1-44) is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV), yielding a plasma half-life of under 10 minutes. CJC-1295 without DAC (also marketed as Modified GRF(1-29) or Mod-GRF(1-29)) addresses this through four amino acid substitutions at positions 2, 8, 15, and 27 that confer DPP-IV resistance. Half-life extends to roughly 30 minutes while full GHRH receptor agonism is retained.

The DAC (Drug Affinity Complex) variant achieves a multi-day half-life through covalent albumin binding via a maleimide-lysine linkage. That fundamentally changes the pharmacodynamic profile from pulsatile to sustained, raising GH levels continuously rather than producing discrete pulses. The physiological implications matter: continuous GH elevation more closely mimics pathological states (acromegaly) than the normal pulsatile pattern.

Published Human Evidence

CJC-1295 is notable for having published human pharmacokinetic and pharmacodynamic data — relatively rare in the research peptide space. Alba and colleagues demonstrated dose-dependent increases in serum GH (2–10 fold above baseline) and sustained IGF-1 elevations lasting 7–14 days after a single injection of CJC-1295 with DAC in healthy adults.

A single injection of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more, with elevated IGF-1 levels persisting for up to 14 days.

— Alba M et al., Journal of Clinical Endocrinology & Metabolism, 2006

This human data — while from a small, early-stage study — demonstrates that the pharmacodynamic activity observed in animal models does translate to humans in the GH/IGF-1 axis. It does not, however, demonstrate that this GH elevation produces meaningful clinical benefits, nor does it characterize long-term safety.

Safety Considerations for GH Secretagogues

GH secretagogues carry safety concerns related to the downstream effects of elevated GH and IGF-1:

• Water retention and edema: GH elevation causes sodium and water retention; peripheral edema is the most commonly reported adverse effect in GH research
• Insulin resistance: Chronic GH elevation antagonizes insulin signaling in muscle and adipose tissue; relevant for diabetic or pre-diabetic individuals
• Carpal tunnel syndrome: A known complication of excess GH (seen in acromegaly and GH therapy), related to fluid accumulation in the carpal tunnel
• Theoretical cancer risk: IGF-1 is a potent mitogen. Pooled-analysis epidemiology (Travis et al., Cancer Research 2016) links higher circulating IGF-I to increased prostate cancer risk, and a meta-analysis of acromegaly cohorts (Dal et al., JCEM 2018) reports a pooled SIR ~1.5 for overall cancer incidence — the closest mechanism-based analog for chronic IGF-1 elevation. GH secretagogues at research doses produce far smaller IGF-1 elevations than untreated acromegaly, but the mechanism-based concern about supporting growth of pre-existing tumors recurs in research-community discussion and is most relevant for individuals with a personal or family cancer history.
• Pituitary desensitization: Chronic receptor stimulation can downregulate GHS-R1a and GHRH receptor sensitivity; cycling protocols are typically employed in research to mitigate this
• WADA prohibition: GH secretagogues including ipamorelin and CJC-1295 are listed on the WADA Prohibited List as S2 Peptide Hormones and are prohibited in sport

Synergy and Research Implications

The complementary mechanisms of CJC-1295 (GHRH pathway) and Ipamorelin (ghrelin/GHS-R1a pathway) make them among the most potent non-pharmacological GH stimulation approaches available for research. The combination maximizes GH pulse amplitude while preserving pulsatile release patterns — theoretically more physiological than continuous elevation.

Downstream effects studied include IGF-1 increases over 4–12 week protocols, nitrogen retention, lean mass changes, lipolytic effects, and sleep quality metrics. Human studies showing meaningful clinical endpoints (not just biomarkers) remain limited. Long-term safety of chronic GH axis stimulation at research doses — particularly regarding cancer risk and metabolic effects — has not been established in controlled trials.

Questions and answers

Why are a GHRH analogue and a GHRP studied together?

Because pituitary growth hormone secretion is governed by two systems: GHRH acts on the GHRH receptor, and the GHRPs act through GHS-R1a on the same cells, converging through separate G-protein cascades. Activating both at once produces a supra-additive pulse, and human studies have shown combined administration exceeding what either produces alone by factors of three to ten.

What makes Ipamorelin different from earlier GHRPs?

Receptor selectivity. It stimulates growth hormone release without meaningfully elevating cortisol, prolactin or ACTH at research-relevant doses, whereas GHRP-2 and GHRP-6 strongly activate those off-target pathways, which limits their utility as research tools. Its half-life is roughly two hours, producing discrete pulses rather than sustained elevation.

What is the difference between CJC-1295 with and without DAC?

Without DAC, four amino acid substitutions confer resistance to dipeptidyl peptidase IV and extend the half-life to roughly 30 minutes while retaining full GHRH receptor agonism. The DAC variant reaches a multi-day half-life through covalent albumin binding, which changes the profile from pulsatile to sustained. Continuous elevation more closely resembles pathological states than the normal pulsatile pattern.

What are the safety concerns for growth hormone secretagogues?

Water retention and peripheral edema, the most commonly reported adverse effect in growth hormone research. Insulin resistance, since chronic elevation antagonises insulin signalling in muscle and adipose tissue. Carpal tunnel syndrome, related to fluid accumulation. And a theoretical cancer concern, because IGF-1 is a potent mitogen: pooled epidemiology links higher circulating IGF-I to increased prostate cancer risk, and a meta-analysis of acromegaly cohorts reports a pooled standardised incidence ratio of about 1.5 for overall cancer incidence. Long-term safety of chronic stimulation at research doses has not been established in controlled trials.